Comprehensive Analysis of Pulmonary Function Test (PFT) Changes After Stereotactic Body Radiotherapy (SBRT) for Stage I Lung Cancer in Medically Inoperable Patients

Abstract

(1) SBRT was well tolerated and PFT changes were minimal. (2) Central lesions were safely treated with 50 Gy.

Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study

“…In a previous study by Henderson et al [23], baseline FEV 1 significantly predicted for post-treatment survival, and patients with poor pulmonary function had significantly better survival. Another study, from Stephans et al [24], showed similar results. As underlined by Stanic et al [10], these findings might be explained by the higher rate of deaths in patients medically inoperable for reasons other than poor pulmonary function.…”

“…This recommendation is based on the results of several prospective phase II trials [2], [3], [4], [5] and [6], as well as large observational studies [7], [8] and [9], with variable follow-up intervals: most of them were limited to spirometric parameters and diffusing capacity for carbon monoxide (Diffusion Lung capacity for Carbon monoxide, D L CO). Recently, a more comprehensive analysis of "complete" Pulmonary Function Tests (including blood gas analysis) was reported, on a series of patients enrolled in the RTOG 0236 phase II trial of SABR in inoperable patients [10].…”

Lung segmentectomy: does it offer a real functional benefit over lobectomy?

“…No proper comparison of SABR and segmentectomy functional consequences can be performed because of the lack of randomised trials. Several studies report PFT measured before and after SABR, but a comparison with surgical series is hazardous because of strong differences in patient characteristics ( patients in SABR studies are older and have more degraded lung function) and study design [35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54]. The SABR PFT results suggest that the mean loss of lung function may be lower after SABR than after segmentectomy, but this needs to be confirmed.…”

Lung stereotactic ablative radiotherapy (SABR): dosimetric considerations for chest wall toxicity

“…[1][2][3] Fatigue, pulmonary toxicity, chest wall toxicity and brachial plexopathy are reported side effects. [2][3][4][5][6][7] Chest wall toxicity includes skin reactions (erythema, ulceration and fibrosis), chest wall pain and rib fracture. 5,[8][9][10] The duration of chest wall pain varies from transient to several weeks or longer and usually occurs more than 6 months after SABR.…”